[ap-intact] NEW PUBLICATION: Asia-Pacific Fraud Survey 2015 - A life sciences perspective
[Facilitator's note: Thank you to Anga R. Timilsina, Programme Manager, UNDP’s Global Anti-corruption Initiative (GAIN), for sharing this information.]
According to Ernst & Young's (EY) Asia-Pacific Fraud Survey 2015: a life sciences perspective, almost three-quarters of life sciences respondents agree that corruption happens widely in their sector – significantly higher than the Asia-Pacific average.
More in EY. http://www.ey.com/SG/en/Services/Assurance/Fraud-Investigation---Dispute-Services/EY-growing-fraud-and-corruption-risks-life-sciences?utm_source=EYCOM&utm_medium=FIDSRHF&utm_campaign=APAC-Fraud-Survey-life-sciences
Note: The survey defines the life sciences sector as comprising pharmaceutical companies, biotechnology companies, medical technology companies and supporting entities such as outsource manufacturers and distributors.
According to Ernst & Young's (EY) Asia-Pacific Fraud Survey 2015: a life sciences perspective, almost three-quarters of life sciences respondents agree that corruption happens widely in their sector – significantly higher than the Asia-Pacific average.
More in EY. http://www.ey.com/SG/en/Services/Assurance/Fraud-Investigation---Dispute-Services/EY-growing-fraud-and-corruption-risks-life-sciences?utm_source=EYCOM&utm_medium=FIDSRHF&utm_campaign=APAC-Fraud-Survey-life-sciences
Note: The survey defines the life sciences sector as comprising pharmaceutical companies, biotechnology companies, medical technology companies and supporting entities such as outsource manufacturers and distributors.